TRIAMCINOLONE ACETONIDE AQUEOUS NASAL INHALER FOR THE TREATMENT OF SPRING GRASS SEASONAL ALLERGIC RHINITIS IN CHILDREN

Triamcinolone acetonide (TAA) Aqueous nasal inhaler is an effective an d well-tolerated treatment for the symptoms associated with seasonal a llergic rhinitis (SAR). This study compared the safety and efficacy of once-daily administration of TAA Aqueous nasal inhaler (110 mu g and 220 mu g) with placebo in a pediatric population with spring-grass SAR . Two hundred and twenty-three patients (6-11 years of age) were evalu ated in this randomized, placebo-controlled, double-blinded trial. Pat ients received TAA Aqueous nasal inhaler (110 mu g or 220 mu g) or pla cebo once daily for 2 weeks. Rhinitis symptoms (nasal stuffiness, disc harge, sneezing, nasal index, nasal itching, and eye symptoms) mere ev aluated and recorded daily. Both TAA Aqueous nasal inhaler dosages wer e more effective than placebo in relieving the symptoms of SAR over th e 2-week treatment period. Patients in the 110-mu g group had signific antly (P < 0.05) greater mean reductions in nasal stuffiness, nasal di scharge, and nasal index compared to placebo after week 1, week 2, and overall. Patients who received TAA Aqueous nasal inhaler 220 mu g had significantly (P < 0.05) larger mean reductions in nasal stuffiness a fter week 1, week 2, and overall, compared to placebo, with significan t (P 0.034) improvements in nasal stuffiness as early as day 1. Patien t and physician satisfaction effects with both TAA Aqueous nasal inhal er regimens was low and comparable with placebo. This double-blinded, placebo-controlled trial demonstrated that TAA Aqueous nasal inhaler ( 110 mu g and 220 mu g per day) was well tolerated and reduced spring g rass SAR symptoms significantly in children. (Pediatr Asthma Allergy I mmunol 1997;11[2]:129-136.)